14-day Premium Trial Subscription Sign Up For FreeGet Free

Cytokinetics Stock Forecast NASDAQ:CYTK

$38.77 (-0.67%)

Volume: 649k

Closed: Nov 29, 2021

Hollow Logo Score: 2.499

Cytokinetics Stock Forecast

$38.77 (-0.67%)

Volume: 649k

Closed: Nov 29, 2021

Score Hollow Logo 2.499
Which way will CYTK go? Request
Stop-loss: $37.12 (-4.25%)
Key Stats
P/E Ratio -14.22
Beta 1.02
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 37 and the stock is currently not being overbought or oversold

Red day on Monday for Cytokinetics
(Updated on Nov 29, 2021)


Buy or Hold candidate since 2021-11-04 Loss -0.51%

The Cytokinetics stock price fell by -0.67% on the last day (Monday, 29th Nov 2021) from $39.03 to $38.77. and has now fallen 3 days in a row. During the day the stock fluctuated 4.22% from a day low at $38.70 to a day high of $40.34. The price has risen in 7 of the last 10 days, but is still down by -1.07% for this period. Volume has increased on the last day by 144 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 649 thousand shares were bought and sold for approximately $25.15 million.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 25.82% during the next 3 months and, with a 90% probability hold a price between $46.61 and $54.83 at the end of this 3-month period.

Signals & Forecast

A sell signal was issued from a pivot top point on Tuesday, November 09, 2021, and so far it has fallen -7.09%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. Some positive signals were issued as well, and these may have some influence on the near short-term development. The Cytokinetics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $40.22. On a fall, the stock will find some support from the long-term average at approximately $38.00. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal.

Support, Risk & Stop-loss

On the downside, the stock finds support just below today's level from accumulated volume at $34.91 and $33.89. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Cytokinetics finds support just below today's level at $34.91. If this is broken, then the next support from accumulated volume will be at $33.89 and $30.05.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.64 between high and low, or 4.22%. For the last week, the stock has had a daily average volatility of 5.77%.

Our recommended stop-loss: $37.12 (-4.25%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 13 days ago.)

Is Cytokinetics stock A Buy?

Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.

Current score: 2.499

Predicted Opening Price for Cytokinetics of Tuesday, November 30, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 30, 2021 Current price
$39.27 $38.77 (Undervalued)
Buy Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 04, 2021 "HC Wainwright" gave "$58.00 - $62.00" rating for CYTK. The price target was set to $38.57+5.2%.

Volatility and Risk
Daily Average Volatility: 5.77 %
Overall Risk: Very High High Medium Low Very Low
Volatility
5.77 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $38.85
Price: $38.77
Support: $34.91

CYTK Insider Trading Show all Trades

INSIDER POWER

0.590

Last 100 transactions
Buy: 231 882 | Sell: 392 939 (Shares)
Date Action Amount Person Type
Nov 12, 2021 Sell 4 143 Blum Robert I Incentive Stock Option (right to buy)
Nov 12, 2021 Sell 4 143 Blum Robert I Common Stock
Nov 12, 2021 Buy 4 143 Blum Robert I Common Stock
Nov 11, 2021 Sell 2 000 Malik Fady Ibraham Common Stock
Nov 09, 2021 Sell 24 519 Cragg David Non-Qualified Stock Option (right to buy)
Show all Insider Trades
INSIDER POWER

0.590

Last 100 transactions
Buy: 231 882 | Sell: 392 939 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 40.90 5.50 %
40.28 3.89 %
39.89 2.90 %
Current price: 38.77
Support 38.64 -0.33 %
38.26 -1.32 %
37.63 -2.93 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 41.10 6.01 %
40.32 4.00 %
38.85 0.21 %
Current price 38.77
Support 34.91 -9.96%
33.89 -12.59%
30.05 -22.49%

Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is developing tirasemtiv, a fast skeletal muscle troponin activator that is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107, which is in Phase II clinical trials for... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT